Sign in

    Shinya Tsuzuki

    Senior Investment Analyst who most recently specialized in the pharmaceutical and biotechnology sectors at Mizuho Securities

    Shinya Tsuzuki is a Senior Investment Analyst who most recently specialized in the pharmaceutical and biotechnology sectors at Mizuho Securities, where he covered leading Japanese biopharma companies such as SHIONOGI & CO. and Sosei Group. Renowned for his industry insight, Tsuzuki was consistently ranked among the top analysts in Japan, achieving 2nd place in the Nikkei Veritas analyst rankings for 2022 and 2023, and 3rd place in 2024 and 2025. After joining Mizuho Securities in 2018, he established a strong track record and also earned 2nd and 4th place honors in the Extel (formerly Institutional Investor) Biotechnology & Pharmaceuticals analyst rankings in consecutive years. Tsuzuki holds degrees from both the School of Engineering and Graduate School of Engineering at Nagoya University.

    Shinya Tsuzuki's questions to SHIONOGI & CO (SGIOY) leadership

    Shinya Tsuzuki's questions to SHIONOGI & CO (SGIOY) leadership • Q1 2024

    Question

    Shinya Tsuzuki of Mizuho Securities asked for confirmation of the rising number of COVID patients since the April-June period and requested an update on the manufacturing enhancement status for the COVID vaccine.

    Answer

    Takeki Uehara, Corporate Officer, confirmed a gradual increase in infections and sales, driven by Xocova's strong market share. Koji Hanasaki, Executive Officer, detailed the vaccine manufacturing plan, with the first lot at the Akita plant and mass production at the Unigen plant in Gifu, noting that scale-up trials and process improvements are currently underway.

    Ask Fintool Equity Research AI